Development of Group B Streptococcal vaccine
NeoStrep is funded by the European Commission FP7 Programme HEALTH
WP4 Phase I clinical trial with GBS-NN with the aim to document safety of the vaccine and establish the optimal doses for use in Phase IIa. The Phase IIa, will test the response rates, antibody titre's, and the longevity of the response for one year post immunization in a larger group of individuals.
The overall objective of this Work Package is to reach clinical proof of concept through surrogate efficacy makers, hereunder response rates, antibody titre's and duration of immune response.
The specific objectives are:
WORK PACKAGE 4